Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285244 | 1.00 | MGLL (0.38) | MGLLALDH1A1TSHRKMT2ACA1 | |
| SCHEMBL13836035 | 1.00 | MGLL (0.38) | MGLLALDH1A1TSHRKMT2ACA1 | |
| SCHEMBL2457046 | 0.95 | MGLL (0.40) | MGLLALDH1A1TSHRKMT2ACA1 | |
| SCHEMBL513824 | 0.95 | — | — | |
| SCHEMBL2807354 | 0.95 | MGLL (0.40) | MGLLALDH1A1TSHRKMT2ACA1 | |
| SCHEMBL3658220 | 0.95 | MGLL (0.40) | MGLLALDH1A1TSHRKMT2ACA1 | |
| SCHEMBL42220 | 0.95 | MGLL (0.40) | MGLLALDH1A1TSHRKMT2ACA1 | |
| SCHEMBL726729 | 0.95 | MGLL (0.40) | MGLLALDH1A1TSHRKMT2ACA1 | |
| SCHEMBL6926105 | 0.95 | MGLL (0.40) | MGLLALDH1A1TSHRKMT2ACA1 | |
| SCHEMBL14084740 | 0.95 | MGLL (0.40) | MGLLALDH1A1TSHRKMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025124516-A1 | COMPOUND HAVING AKT KINASE-DEGRADING ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 南京正大天晴制药有限公司 | 2025-06-19 | — | — | WO | claimed |
| CN-120157686-A | Compound with AKT kinase degradation activity, preparation method and pharmaceutical application thereof | 南京正大天晴制药有限公司 | 2025-06-17 | — | — | CN | claimed |
| WO-2024012570-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 西藏海思科制药有限公司 | 2024-01-18 | — | — | WO | claimed |
| CN-117229263-A | Compound for inhibiting or degrading Bcl6 and application of compound in medicine | 四川海思科制药有限公司 | 2023-12-15 | — | — | CN | claimed |
| WO-2023232133-A1 | COMPOUND FOR INHIBITING OR DEGRADING BCL6 AND USE THEREOF IN PHARMACEUTICS | 西藏海思科制药有限公司 | 2023-12-07 | — | — | WO | claimed |
| WO-2023208165-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2023-11-02 | — | — | WO | claimed |
| CN-116947877-A | Benzimidazole derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-10-27 | — | — | CN | claimed |
| CN-111372931-B | Heterocyclic compounds as protein kinase inhibitors | 怡诺安有限公司 | 2023-03-24 | — | — | CN | claimed |
| WO-2023016518-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2023-02-16 | — | — | WO | claimed |
| CN-114874286-A | Compound for degrading BTK kinase, pharmaceutical composition and pharmaceutical application thereof | 四川海思科制药有限公司 | 2022-08-09 | — | — | CN | claimed |
| WO-2008006032-A1 | CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | claimed |
| EP-1707563-A2 | Methods and compositions utilizing quinazolinones | Cytokinetics, Inc. (US) | 2006-10-04 | — | — | EP | claimed |
| EP-1686120-A2 | Methods and compositions utilizing quinazolinones | Cytokinetics, Inc. (US) | 2006-08-02 | — | — | EP | claimed |
| US-20040023996-A1 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. | 2004-02-05 | — | — | US | claimed |
| US-6562831-B1 | Inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases | CYTOKINETICS, INC. | 2003-05-13 | — | — | US | claimed |
| EP-1296959-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | Cytokinetics, Inc. (US) | 2003-04-02 | — | — | EP | claimed |
| WO-2001030768-A9 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS INC (US) | 2002-08-15 | — | — | WO | claimed |
| EP-1226129-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | Cytokinetics, Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| WO-2001098278-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001030768-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-05-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023996-A1 | Methods and compositions utilizing quinazolinones | KIF5B, KIF5C, KIF2C | MGLL 4578/4885ALDH1A1 1628/4885TSHR 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.